Frequent coauthors
- KAWASAKI HIROKAZU 84
- OHSHIMA ETSUO 84
- KIMOTO NAOYA 70
- WATANABE AKIKO 14
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.